LigaChem Biosciences Enters License Agreement with GO Therapeutics

- Combination of a novel tumor target with ConjuAll technology enables overcoming on-target toxicity, a key limitation of existing solid tumor therapies
- Advancing ADCs for high unmet medical needs including lung, breast, ovarian and colorectal cancers

Daejeon, Republic of Korea – September 9, **2025 -** LigaChem Biosciences (141080KS, hereinafter "LigaChemBio") announced on September 9th that it has entered into a licensing agreement with U.S.-based GO Therapeutics Inc. (hereinafter "GO Therapeutics"). Under the agreement, LigaChemBio receives worldwide license to develop and commercialize antibody-drug conjugates (ADCs) incorporating GO Therapeutics' antibody. Specific terms of the agreement remain confidential under contractual obligations.

The licensed antibody leverages GO Therapeutics' next-generation targeting approach to identify tumor specific antigens expressed solely on tumor cells with no concurrent expression on healthy normal cells. This approach is aimed at overcoming on-target toxicity, a key limitation of many solid tumor therapies caused by the expression of target antigens on normal cells. LigaChemBio plans to develop ADCs addressing high unmet needs across multiple solid tumors, including lung, breast, ovarian and colorectal cancer.

"Including this agreement with GO Therapeutics, we have licensed five new oncology target antibodies in 2025 alone" said Yong-Zu Kim, CEO of LigaChemBio. "We will continue building a novel ADC pipeline with high global licensing potential by strengthening joint research and strategic partnerships with Korean and global partners, expanding beyond antibodies to innovative ADC payloads."

“We are excited to collaborate with LigaChemBio to translate our tumor-selective targeting into first-in-class ADCs, said Constantine Theodoropulos, CEO of GO Therapeutics. “Combining GO’s novel cancer targeting innovation with LigaChemBio’s ADC expertise has the potential to deliver safer, more effective treatments for patients with difficult-to-treat solid tumors.”

This agreement is part of LigaChemBio’s VISION 2030 strategy to identify three to five new ADC candidates annually and rapidly advance them into clinical trials, with an emphasis on fast-to-clinic antibody-based programs and continued pipeline expansion.